Navigation Links
Allegheny General Hospital Study Suggests Use of Image Guided Intensity Modulated Radiation Therapy Reduces Risk of Impotency in Men Needing Radiation after Prostate Cancer Surgery
Date:11/2/2010

PITTSBURGH, Nov. 2, 2010 /PRNewswire-USNewswire/ -- Men battling prostate cancer who receive Image Guided Intensity Modulated Radiation Therapy after undergoing prostatectomy have an excellent chance of retaining sexual function, according to a study by Allegheny General Hospital (AGH) cancer specialists presented this week at the annual meeting of the American Society for Therapeutic Radiation and Oncology in San Diego.

Each year in the United States about 200,000 men are diagnosed with prostate cancer. It is the second most common cancer among men, second only to skin cancer.  Most men with prostate cancer are over age 65, and the disease disproportionately strikes African-American men.

"Any cancer diagnosis can impact quality of life, but a prostate cancer diagnosis can be particularly difficult for men because impotence is a common side effect of treatment," said Russell Fuhrer, MD. "While recent improvements have made loss of potency less common after prostate cancer therapy, men must still take this complication into account as they decide on a treatment plan."

The AGH study, "Preservation of Sexual Function After High-Dose Post Prostatectomy Image Guided Intensity-Modulated Radiation Therapy (IMRT)," looked at 33 patients who underwent prostate removal surgery using open or robotic nerve-sparing techniques, followed by Image Guided IMRT radiotherapy.

Image Guided IMRT is an advanced type of radiotherapy in which computer-controlled linear accelerators direct radiation precisely to the tumor, sparing surrounding healthy tissues. Used extensively to treat prostate cancer, Image guided IMRT allows a higher, more focused and effective dose of radiation to the tumor.

Before radiotherapy, the men assessed their sexual function using a self-administered questionnaire called SHIM, Sexual Health Inventory for Men. For men who qualified as potent, researchers again used the SHIM test to measure their potency after radiotherapy.

Among men in the AGH study who were potent at the beginning of radiation therapy, 71 percent maintained potency at 27 months following radiotherapy with Image guided IMRT.

"These results suggest that men who must undergo radiotherapy following a prostatectomy can be confident that they have an excellent chance of maintaining potency after treatment when Image guided IMRT is used," Dr. Fuhrer said.


'/>"/>
SOURCE West Penn Allegheny Health System
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pennsylvania Agriculture Department Issues Quarantine for Allegheny County Horse Stable
2. Allegheny General Hospital Performs First Liver Transplant
3. Accuray Hires General Manager for the Asia Pacific Region
4. General Dynamics Awarded Contract to Outfit and Transition U.S. Army Medical Facilities
5. Lotus Pharmaceuticals Retains Sichenzia Ross Friedman Ference LLP as General Legal Counsel
6. North American Spine Partners With University General Hospital to Bring Back Pain Relief to Houston Patients
7. US Oncology Announces Addition of John Osborn as EVP & General Counsel and Asif Ahmad as EVP of Technology Services
8. Simcere Pharmaceutical Group Provides Notice of Annual General Meeting
9. Vanda Pharmaceuticals Adds Former U.S. Surgeon General, Steven Galson, to its Board of Directors
10. Xacore Partners With ESSE, Headed by Retired Army Four Star General, to Tackle Military Hearing Loss
11. Acuo Technologies Announces Implementation and Acceptance of Acuos DICOM Services Grid(TM) With Lancaster General Hospital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... Blood Monitoring & Cardiac Monitoring Devices Market Assessment & Forecast: 2015-2019" ... market for blood monitoring & cardiac monitoring devices was valued at ... 24,830.1 million by 2019 at a CAGR of 6.8% from 2015 ... Europe , Asia-Pacific , Latin ... Africa . The three major factors determining growth of the ...
(Date:2/9/2016)... , Feb. 9, 2016 The life of Dr. ... Center, has been anything but ordinary.  Twists of fate, combined ... War II and the constraints of communist Czechoslovakia to ... he would go on to make history by playing a ... best-selling drugs in the world, Remicade.  Dr. Vilcek brings readers ...
(Date:2/9/2016)... KONG , Feb. 9, 2016 Athenex, Inc. ... Athenex as Vice President of Corporate Strategy and Business Development ... MSc, MBA has joined as Senior Director and Deputy Head of Clinical ... . Simon Pedder stated, "Athenex has ... for a while. Coupled together with their unique business model ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... ... Gout is like no other joint pain. It strikes suddenly, like flicking on ... redness. It is triggered by the crystallization of uric acid within the joints. It ... to the February 2016 issue of Harvard Men's Health Watch. , The large joint ...
(Date:2/10/2016)... ... February 10, 2016 , ... AHRA: The Association for ... speaker Jan Fox will serve as keynote speaker at the organization’s 2016 Spring ... tools to more effectively communicate with their own organizational staff and leadership. ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... will attend the Ohio Safety Congress and Expo event March 9-11, 2016. Hosted ... Greater Columbus Convention Center. , As the longest running and largest worker's ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... biocompatible columns and accessories. These PEEK-lined stainless steel (PLS) columns combine the strength ... solution that ensures the integrity of biological samples while operating at ultra-high pressures ...
(Date:2/10/2016)... CA (PRWEB) , ... February 10, 2016 , ... Workrite ... based company that has evolved from humble beginnings to being an internationally recognized leader ... company that we are today”, said Charlie Lawrence, President of Workrite. “Workrite recognized ...
Breaking Medicine News(10 mins):